HPS masthead
search
What's New?
. April Newsletter
. April Journal
Upcoming Events
. 2010 Summer Professional Development School
Internal Dosimetry
23 - 26 June 2010
Idaho State University, Pocatello, Idaho
. International Conference on Radiation Protection in Medicine
1-3 September 2010
Varna, Bulgaria
. 2010 Meeting of the Air Monitoring Users Group
4-7 May 2010
Las Vegas, NV
19 March 2010

Answer to Question #1172 Submitted to "Ask the Experts"

Category: Policy, Guidelines, and Regulations

The following question was answered by an expert in the appropriate field:

Q
What is the Nuclear Regulatory Commission's current requirement for bioassay of individuals involved in the administration of outpatient doses of 131I in capsule form, in excess of 33 mCi?
A
The current requirements are specified in both the Nuclear Regulatory Commission's (NRC) Part 20 and Part 35 regulations. The more general requirement, in Part 20, specifies that any worker who is likely to receive in a year in excess of 10% of the annual limit on intake (ALI) must be monitored for intake. For 131I, this would normally be, in effect, a requirement to perform bioassays. The determination of who is to be monitored under this requirement must be made prospectively, that is, at the beginning of the monitoring period (normally the start of the calendar year). The more specific requirement is in Part 35, which requires that, for staff who helped prepare or administer a dosage of 131I to patients who were hospitalized for compliance with the patient-release criteria, a measurement of thyroid burden must be made within three days of such administration. Although both Part 20 and Part 35 requirements apply, the general rule is that the specific requirement, in this case Part 35, takes precedence over the general requirement. It should be noted that some licensees may have somewhat different requirements incorporated into their licenses. For example, many licensees incorporate the programs described in NRC's Regulatory Guide 10.8 into their licenses. In that case, the requirement is to measure thyroid burden one day after administration of over 30 mCi of 131I and to consider a measurement two days after administration. In the revised Part 35, which is not yet in effect, the specific requirement in Part 35 is deleted, and the licensee will in that case be expected to comply with the more general, Part 20, requirement.

Sami Sherbini NRC
Answer posted on 19 October 2001. The information and material posted on this Web site is intended as general reference information only. Specific facts and circumstances may alter the concepts and applications of materials and information described herein. The information provided is not a substitute for professional advice and should not be relied upon in the absence of such professional advice specific to whatever facts and circumstances are presented in any given situation. Answers are correct at the time they are posted on the Web site. Be advised that over time, some requirements could change, new data could be made available, or Internet links could change. For answers that have been posted for several months or longer, please check the current status of the posted information prior to using the responses for specific applications.
Home Affiliates Ask the Experts Radiation Terms Employment Meetings